Anti-cytolethal distending toxin antibodies in systemic sclerosis: associations with gastrointestinal disease and immune dysregulation

Systemic Sclerosis

Serum IL-40 is elevated in systemic sclerosis and is linked to disease activity, gastrointestinal involvement, immune regulation and fibrotic processes

Arthritis Res Ther

Navrátilová A, Oreská S, Wünsch H, Mocová K, Kodet O, Rybar M, Alquicer G, Prokopcová A, Bečvář V, Bečvář R, Jiránková A, Bobrová A, Bobrová K, Pavelka K, Vencovský J, Šenolt L, Cerezo LA, Tomčík M

doi: 10.1186/s13075-025-03570-3

Systemic Sclerosis

Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort

Rheumatology (Oxford)

Roth E, Bruni C, Petelytska L, Becker MO, Dobrota R, Jordan S, Mihai C, Muraru S, Carreira PE, De Vries-Bouwstra J, Braun-Moscovici Y, Liakouli V, Moroncini G, Bergmann C, Mouthon L, Denton CP, De Santis M, Cauli A, Adler S, Bernardino V, Truchetet ME, Vonk M, Del Galdo F, Hoffmann-Vold AM, Distler O, Elhai M, EUSTAR collaborators

doi: 10.1093/rheumatology/keaf016

Further Publications Immunology

Evaluating renal disease in pediatric-onset anti-neutrophil cytoplasmic antibody-associated vasculitis: disease course, outcomes, and predictors of outcome

Arthritis Rheumatol

Toor KK, Chen A, Cabral DA, Mammen C, Bosman ES, Shen Y, Bone JN, Noone D, Al-Abadi E, Benseler S, Berard R, Bohm M, Charuvanij S, Cook K, Dancey P, Deepak S, Duffy C, Eberhard B, Elder M, Foell D, Gerstbacher D, Heshin-Bekenstein M, Huber A, James KE, Kim S, Klein-Gitelman M, Martin N, McErlane F, Moorthy LN, Myrup C, Riley P, Shenoi S, Sivaraman V, Tanner T, Tarvin S, Wagner-Weiner L, Yeung RSM, Brown KL, Morishita KA, PedVas Investigator's Network

doi: 10.1002/art.43071

Systemic Lupus Erythematosus

Systemic lupus erythematosus-disease activity score remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in systemic lupus erythematosus remission and lupus low disease activity state

Rheumatology (Oxford)

Nakanishi E, Matsushita M, Minowa K, Tada K, Kawamoto T, Kusaoi M, Amano H, Kon T, Morimoto S, Ikeda K, Suzuki S, Nozawa K, Yang KS, Matsudaira R, Katagiri A, Tsushima H, Urasaki W, Nojiri S, Yamaji K, Tamura N

doi: 10.1093/rheumatology/keaf349

Systemic Lupus Erythematosus

Genetic variability associates with ancestry, age at disease onset, organ involvement and disease severity in juvenile-onset systemic lupus erythematosus

Clin Immunol

Natoli V, Charras A, Hasoon MSR, Jorgensen AL, Smith EMD, Gutiérrez EC, Beresford MW, Hedrich CM, UK JSLE Cohort Study Group

doi: 10.1016/j.clim.2025.110540

Further Publications Rheumatology

Dry eye disease and spondyloarthritis: expanding the spectrum of systemic inflammatory disorders associated with ocular surface disease. Data from the international AIDA Network Spondyloarthritis Registry

Front Med (Lausanne)

Vitale A, Caggiano V, Martín-Nares E, Di Meglio N, Sica C, Hinojosa-Azaola A, Perfetti MO, Pagliara A, Guidetti G, Fonollosa A, Lopez R, Sbalchiero J, Sota J, Carreño E, Kawakami-Campos PA, Gentileschi S, de-la-Torre A, Tosi GM, Mazzei MA, Balistreri A, Frediani B, Cantarini L, Fabiani C

doi: 10.3389/fmed.2024.1422307

Systemic Sclerosis

Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort Study

J Autoimmun

Chaigne B, Bense A, Aubourg F, Agard C, Allanore Y, Berezne A, Pugnet G, Hachulla E, Cottin V, Hot A, Dunogue B, Kanagaratnam A, Palat S, Lescoat A, Berthier S, Chatelus E, Rivière S, Launay D, Truchetet ME, Dinh-Xuan AT, Mouthon L, French Systemic Sclerosis Network

doi: 10.1016/j.jaut.2025.103391

Systemic Sclerosis

Fatigue levels and associated factors in systemic sclerosis: a cross-sectional study of 2,385 SPIN Cohort participants

Rheumatology (Oxford)

Kwakkenbos L, Levis B, Henry RS, Virgili-Gervais G, Carrier ME, Bartlett SJ, Gietzen A, Gottesman K, Guillot G, Lawrie-Jones A, Hummers LK, Malcarne VL, Mayes MD, Richard M, Wojeck RK, Worron-Sauvé M, Hudson M, Mouthon L, Benedetti A, Thombs BD

doi: 10.1093/rheumatology/keae570

Systemic Sclerosis

Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis

Rheumatology (Oxford)

Goldman NR, Nihtyanova SI, Beesley CF, Wells AU, Denton CP, Renzoni EA, Mageed R, Ong VH

doi: 10.1093/rheumatology/keaf006

Related content

Serum IL-40 is elevated in systemic sclerosis and is linked to disease activity, gastrointestinal involvement, immune regulation and fibrotic processes

Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort

Evaluating renal disease in pediatric-onset anti-neutrophil cytoplasmic antibody-associated vasculitis: disease course, outcomes, and predictors of outcome

Systemic lupus erythematosus-disease activity score remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in systemic lupus erythematosus remission and lupus low disease activity state

Genetic variability associates with ancestry, age at disease onset, organ involvement and disease severity in juvenile-onset systemic lupus erythematosus

Dry eye disease and spondyloarthritis: expanding the spectrum of systemic inflammatory disorders associated with ocular surface disease. Data from the international AIDA Network Spondyloarthritis Registry

Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort Study

Fatigue levels and associated factors in systemic sclerosis: a cross-sectional study of 2,385 SPIN Cohort participants

Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis